View in EDS

Trends of all-cause, melanoma-specific, and cardiovascular mortality in melanoma patients from 2005 to 2020

Saved in:
Bibliographic Details
Title: Trends of all-cause, melanoma-specific, and cardiovascular mortality in melanoma patients from 2005 to 2020
Authors: Prasai, Astha, Baral, Nischit, Elajami, Mohamad K, Vallabhaneni, Esha, Mitchell, Joshua D, Iqbal, Uzma, Bahmad, Hisham F, Welty, Francine K, Elajami, Tarec K
Source: Rochester Regional Health authored publications and proceedings
Publisher Information: RocScholar
Publication Year: 2025
Subject Terms: Cardio-oncology, Cardiovascular Mortality, Melanoma, Melanoma-specific mortality, Humans, Melanoma (mortality, epidemiology, complications), Male, Female, Cardiovascular Diseases (mortality), SEER Program (statistics & numerical data), Middle Aged, Aged, Incidence, Skin Neoplasms (mortality, epidemiology), Adult, United States (epidemiology), Mortality (trends), Cause of Death (trends), 80 and over, Young Adult, Medicine and Health Sciences
Description: Background: Recent advances in melanoma treatment, including immunotherapy and targeted therapy, have significantly improved survival among melanoma patients after 2010. However, these changes may have influenced mortality trends, including those related to cardiovascular (CV) events. Objective: In this study, we assess mortality trends including CV mortality in melanoma patients. Methods: Using data from the Surveillance, Epidemiology, and End Results (SEER) 17 registry, we examined melanoma incidence and CV, melanoma-specific, and all-cause mortalities from 2005 to 2020. We utilized Joinpoint software to estimate the annual percentage change (APC). Results: Our study included 299,993 melanoma patients (173,889 males; 126,104 females). The incidence of melanoma increased by 0.6 % annually (95 % CI: 0.3-1.5, p < 0.05) from 2005 to 2019, followed by a 6.3 % decrease (95 % CI: -9.9 to -0.7, p < 0.05) in 2020. All-cause mortality increased annually by 8.3 % (95 % CI: 6.7-11.3, p < 0.05) from 2005 to 2010, then by 3.3 % (95 % CI: 2.8-3.7, p < 0.05) after 2010. Melanoma-specific mortality increased by 2.0 % annually (95 % CI: 0.8-3.5, p < 0.05) from 2005 until 2013, after which it declined by 5.1 % (95 % CI: -7.3 to -3.8, p < 0.05). CV mortality increased by 7.1 % annually (95 % CI: 4.6-9.4, p < 0.05) from 2005 to 2020. Trends were similar across sexes, with a non-significant higher APC in CV mortality noted among females from 2017 to 2020. Conclusions: Our study shows despite the significant decrease in all-cause and melanoma-specific mortalities after 2010, likely reflecting the benefits of modern therapies, CV mortality continued to rise. These findings underscore the need for long-term surveillance and CV risk management in melanoma patients.
Document Type: text
Language: unknown
Relation: https://scholar.rochesterregional.org/rrhpubs/2882; https://doi.org/10.1016/j.canep.2025.102848
DOI: 10.1016/j.canep.2025.102848
Availability: https://scholar.rochesterregional.org/rrhpubs/2882
https://doi.org/10.1016/j.canep.2025.102848
Accession Number: edsbas.D6E88B94
Database: BASE
Description
Abstract:Background: Recent advances in melanoma treatment, including immunotherapy and targeted therapy, have significantly improved survival among melanoma patients after 2010. However, these changes may have influenced mortality trends, including those related to cardiovascular (CV) events. Objective: In this study, we assess mortality trends including CV mortality in melanoma patients. Methods: Using data from the Surveillance, Epidemiology, and End Results (SEER) 17 registry, we examined melanoma incidence and CV, melanoma-specific, and all-cause mortalities from 2005 to 2020. We utilized Joinpoint software to estimate the annual percentage change (APC). Results: Our study included 299,993 melanoma patients (173,889 males; 126,104 females). The incidence of melanoma increased by 0.6 % annually (95 % CI: 0.3-1.5, p < 0.05) from 2005 to 2019, followed by a 6.3 % decrease (95 % CI: -9.9 to -0.7, p < 0.05) in 2020. All-cause mortality increased annually by 8.3 % (95 % CI: 6.7-11.3, p < 0.05) from 2005 to 2010, then by 3.3 % (95 % CI: 2.8-3.7, p < 0.05) after 2010. Melanoma-specific mortality increased by 2.0 % annually (95 % CI: 0.8-3.5, p < 0.05) from 2005 until 2013, after which it declined by 5.1 % (95 % CI: -7.3 to -3.8, p < 0.05). CV mortality increased by 7.1 % annually (95 % CI: 4.6-9.4, p < 0.05) from 2005 to 2020. Trends were similar across sexes, with a non-significant higher APC in CV mortality noted among females from 2017 to 2020. Conclusions: Our study shows despite the significant decrease in all-cause and melanoma-specific mortalities after 2010, likely reflecting the benefits of modern therapies, CV mortality continued to rise. These findings underscore the need for long-term surveillance and CV risk management in melanoma patients.
DOI:10.1016/j.canep.2025.102848